title: Comparative study of plasma gastrin levels in rats after two months of ebrotidine administration.
abstract: Four groups of male rats were orally administered for 60 days with daily doses of ebrotidine (N-[(E)-[[2-[[[2-[(diaminoethylene) amino]-4-thiazolyl]methyl]thio]ethyl]amino]methylene]-4-bromo- benzenesulfonamide, CAS 100981-43-9, FI-3542) (500 mg/kg), ranitidine (500 mg/kg), cimetidine (500 mg/kg) and omeprazole (43.5 mg/kg). A fifth group received no treatment and was used as control. The curve of gastrinemia was obtained on days 1, 15 and 60 of administration. On each of these days gastrinemia was assessed at 0, 1, 5, 8, and 24 h on day 1, and 1, 5, 8, 10 and 24 h on days 15 and 60. The purpose of this study was to compare the plasma gastrin level profile in association with the administration of test drugs on days 1, 15 and 60 of treatment. The results showed a significant difference in the duration of hypergastrinemia of H2-receptor antagonists as compared to proton pump blockers. Although peak plasma gastrin levels were attained for all products between 5 and 8 h after day 1 of administration, H2-receptor antagonists, unlike omeprazole, achieved recovery of gastrin baseline levels within 24 h. On days 15 and 60 of ebrotidine, treatment, plasma gastrin levels returned to normal range at 5 and 8 h after administration, respectively. After ranitidine and cimetidine, hypergastrinemia was still present at this time, but normal levels were attained before 24 h. With omeprazole plasma gastrin levels did not return to normal range within 24 h after each administration, and a cumulative effect occurred during treatment. The omeprazole treated group showed the highest and more sustained plasma gastrin levels. It was concluded that ebrotidine was the antisecretory agent with the lowest hypergastrinemic effect during long-term treatment. With ebrotidine daily baseline gastrin levels were more rapidly recovered after each administration.
authors.affiliation: Department of Toxicology, Centro de Investigación Farmacéutica Grupo Ferrer, Barcelona, Spain.
authors.forename: A
authors.initials: A
authors.lastname: Romero
authors.forename: F
authors.initials: F
authors.lastname: Gómez
authors.forename: F
authors.initials: F
authors.lastname: Villamayor
authors.forename: A
authors.initials: A
authors.lastname: Ballesta
authors.forename: A
authors.initials: A
authors.lastname: Sacristán
authors.forename: J A
authors.initials: JA
authors.lastname: Ortiz
mesh_terms: D000818:Animals; D001557:Benzenesulfonates / Q000008:administration & dosage / Q000494:pharmacology*; D002927:Cimetidine / Q000494:pharmacology; D005755:Gastrins / Q000097:blood*; D006635:Histamine H2 Antagonists / Q000008:administration & dosage / Q000494:pharmacology*; D008297:Male; D009853:Omeprazole / Q000494:pharmacology; D011899:Ranitidine / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D013047:Specific Pathogen-Free Organisms; D013844:Thiazoles / Q000008:administration & dosage / Q000494:pharmacology*
chemical_list: D001557:Benzenesulfonates; D005755:Gastrins; D006635:Histamine H2 Antagonists; D013844:Thiazoles; D002927:Cimetidine; D011899:Ranitidine; D009853:Omeprazole; C075156:ebrotidine